CN1260717A - 1－芳(烷)基咪唑啉－2－酮在治疗焦虑和紧张状态中的应用 - Google Patents
1－芳(烷)基咪唑啉－2－酮在治疗焦虑和紧张状态中的应用 Download PDFInfo
- Publication number
- CN1260717A CN1260717A CN98805374A CN98805374A CN1260717A CN 1260717 A CN1260717 A CN 1260717A CN 98805374 A CN98805374 A CN 98805374A CN 98805374 A CN98805374 A CN 98805374A CN 1260717 A CN1260717 A CN 1260717A
- Authority
- CN
- China
- Prior art keywords
- imidazoline
- anxiety
- general formula
- effect
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 30
- 230000036506 anxiety Effects 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001118 alkylidene group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000006073 displacement reaction Methods 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- ADOLLNOHUDQRCE-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-morpholin-4-ylimidazolidin-2-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)NC(N2CCOCC2)C1 ADOLLNOHUDQRCE-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 7
- 229960003120 clonazepam Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及通式Ⅰ的1－芳(烷)基咪唑啉－2－酮或其可药用盐在治疗焦虑和紧张性疾病的应用。1－(4－氯苯基)－4－吗啉—咪唑啉－2－酮作为一个实施例。
Description
本发明涉及通式I的1-芳(烷)基咪唑啉-2-酮或其可药用盐在治疗焦虑和紧张性疾病的应用。
在德国19532668.7号专利申请中记载了通式I的化合物：n＝0，1m＝0，1，2，3，4，5
其中X＝氢、C1-C4烷基、C1-C4烷氧基、三氟甲基、卤素，
R1和R2＝C1-C4烷基、环烷基、杂原子取代的烷基或者
R1和R2共同为具有2-6个碳原子的亚烷基，并且该亚烷基中的一个CH2可被氧、氮或硫置换，CH2的数目可以是0(1-芳基-咪唑啉-2-酮)或1(1-芳烷基咪唑啉-2-酮)。
药理学结果表明：通式I的化合物适合治疗各种癫痫。
直至今天，各种原因和程度的焦虑和紧张状态并不是在所有情况下均能得到满意的治疗。大约从1960年以来，苯并二氮杂衍生物已经用作一种治疗焦虑和紧张性疾病的优选物质。具有这种性质的物质通常具有镇静和情绪衰减作用。简言之，这些药物是非常有用的，但是即使在治疗剂量情况下，也产生副作用如镇静、嗜睡和反应性降低。
由于镇静作用，从而对精神活动有副作用。在一定程度上，会观测到影响功能的运动失调和协调性障碍。持续用药时，这些苯并二氮杂类化合物可以导致习惯性作用，即所谓的耐受性。因此，制剂的疗效降低，用药剂量必须加大。并可发展为心理依赖性甚至生理依赖性。因此在停药试验中产生停药综合症。
已经上市的抗焦虑药中最典型的代表为活性化合物安定、氯硝基安定、去氧安定。
安定为了达到抗焦虑作用，必须具有300-400mg/ml(sic)的血浆浓度。然而，在同样浓度下，同样产生上面提到的副作用例如：镇静、精神性运动障碍表现为白天的镇静、催眠以及注意力和反应性降低。由于安定和氯硝基安定半衰期长，因此产生严重的“宿醉”(hang-over)作用，同样地伴有嗜睡、智力和运动能力减退以及反应减慢。氯硝基安定的抗焦虑作用被其镇静催眠作用所掩盖。高剂量的去氧安定同样有嗜睡和肌肉松弛现象。
这三种药物均能增强许多中枢活性药物和酒精的作用。这样，服用单个药物后，其效果几乎看不出来。
迄今为此，对于相对长期的焦虑状态，其治疗效果一直不能令人满意。目前，尚不能确保抗焦虑药物的长期治疗作用。
因此，本发明的目的是提供有效的药物用于治疗各种焦虑和紧张状态，并且其有非常大的治疗宽度。
令人惊奇的是，已经发现：在动物试验中，通式I的化合物具有显著的抗焦虑作用并且没有镇静的副作用。
药理学研究
研究通式I化合物的目的是评价这些化合物在所研究动物模型中抗焦虑作用可能的效果。为此，使这些动物处于不同的冲突环境中，测定了例如化合物1-(4-氯苯基)-4-吗啉咪唑啉-2-酮(实施例1)的作用。
Vogel冲突测试中抗焦虑的研究
在该模型中，对动物持续供应的饮用水停止一段时间。这段时间过后，再使动物能自由接近饮用水，但接近饮用水处有温和的电刺激。动物的冲突在于：其要么接受电刺激，要么不喝水。
这种冲突环境的反应和第二种人焦虑现象是相似的。产生了回避反应，该回避反应能被抗焦虑物质抑制。抗焦虑作用的测定是这样进行的：确定用测试物质处理的动物所能耐受的电流脉冲的数目，将其与载体处理的对照组进行比较。表1中得到的结果示于图1。 表1在Vogel冲突测试/大鼠中物质的抗焦虑作用X±SEM；*P＜0.05，**P＜0.01
| 物质 | mg/kg p.o. | 脉冲数 | 脉冲变化数目相对于对照组的百分比 |
| 对照实施例1对照 | -1310-30 | 51.4±7.7361.3±8.7283.2±7.19**80.1±9.23**39.6±7.20126.0±15.7** | 19.361.955.8218.0 |
| 对照安定 | -0.10.31.03.0 | 62.3±7.0758.4±6.4770.9±6.8592.1±3.22**104.4±11.9** | -6.313.847.867.6 |
| 对照氯硝基安定 | -0.10.31.0 | 63.9±6.6377.7±8.5481.8±7.81110.3±13.5* | 21.628.072.6 |
| 对照去氧安定 | -0.31.03.0 | 54.6±7.8954.8±8.8571.3±10.042.7±4.54 | 0.430.6-21.8 |
对于实施例1中的化合物，检测其抗焦虑作用，口服剂量从3mg/kg到10mg/kg，其抗焦虑作用并不增强。增加口服剂量到30mg/kg后，有可能检测到作用的加强。安定和氯硝基安定的等效剂量是口服1-3mg/kg和口服1mg/kg。
对于去氧安定，在0.3-3mg/kg的口服剂量范围，不可能检测出其作用。
未处理动物饮水明显减少，这表明它们比用抗焦虑物质处理的动物更焦虑。实施例1中的化合物，从口服3mg/kg开始，动物所耐受电刺激数目明显增加。这种作用确证了通式I化合物具有良好的抗焦虑活性。
因此，可以预料，特别是在冲突环境中，通式I的化合物能够产生抗焦虑作用。
在高位迷宫中抗焦虑的研究
在该模型中，大鼠臂置于具有开臂和关臂的高位通道系统中(Pellow，S.，Chopin，P.，File S.E.，Briley，M.：Validation ofopen：在高位迷宫中关臂进入作为大鼠的焦虑方式，神经学方法杂志(J.of Neuroscience Methods)14：149-167，1985；Hogg，S.：高位迷宫作为焦虑动物模型的有效性和可变性，药理学生物化学和行为(Pharmacology Biochemistry and Behavior：21-30，1996)。未处理动物重复尝试关闭的通道。焦虑的抑制是通过进入开臂的数目和停留在开臂中的时间作为总进入数目的百分比或停留总时间的百分比来测定的。用通式I化合物处理后，进入开臂的数目和停留时间的百分比值增加，这从图2可以看出。经腹膜给药10或30mg/kg实施例1中的化合物后，进入开臂的数目和在开臂中停留时间的比例显著增加。
在药理学试验中，通式I的化合物在抗焦虑作用和镇静作用之间显示出明显的区分。图3中可以明显看出，例如，实施例1的化合物与对照物安定相比，显示出明显较低的镇静作用。
在小鼠中研究了通式I化合物的中枢镇静作用。给动物服用一定量的酒精，注意服用量不能导致任何小鼠侧卧。检测酒精催眠作用被加强的程度，通过另外服用通式I的化合物诱导小鼠侧卧。例如对于实施例1中的化合物，其抗焦虑剂量15-66倍的剂量对酒精的作用仅仅引起较低的和非剂量依赖性的加强。作为对照，研究了抗焦虑剂量范围的安定和氯硝基安定。对于这两个标准的化合物，有可能检测出对酒精作用有明显的和剂量依赖性的加强(图3)。
与对照物质安定和氯硝基安定相比，通式I的化合物仅仅有很低的神经毒性。
在rotorod试验中，实施例1中化合物口服的最低神经毒性剂量确定为998mg/kg。
治疗指数，以rotorod试验中最低神经毒性剂量和抗焦虑剂量的商计算，非常高，达到333，并且有非常大的治疗宽度，这可从图4中看出。
物质的治疗宽度作为一个重要的药理学特性参数，它是治疗作用和毒性作用之间安全性的一个测量尺度。因此，与上市的抗焦虑活性物质相比，通式I中的化合物具有非常大的治疗宽度是更为令人惊奇的。
结果，对焦虑和紧张状态患者的治疗，特别是在相对长的一段时间内的治疗，得到了明显的改进。
可以通过已知的方式把通式I的化合物及其可药用盐转变成药物制剂例如片剂、胶囊、包衣片剂、粒剂、乳剂、混悬剂或溶液剂。
可以应用传统的药用赋形剂和辅料来生产这些制剂。这样，每日剂量应该优选3-30mg/天。
Claims (3)
1、通式I的化合物：n＝0，1m＝0，1，2，3，4，5
其中X＝氢、C1-C4烷基、C1-C4烷氧基、三氟甲基、卤素，
R1和R2＝C1-C4烷基、环烷基、杂原子取代的烷基或者
R1和R2共同为具有2-6个碳原子的亚烷基，并且该亚烷基中的一个CH2可被氧、氮或硫置换，CH2的数目可以是0(1-芳基-咪唑啉-2-酮)或1(1-芳烷基咪唑啉-2-酮)，
及其可药用盐在制备焦虑和紧张状态治疗药物中的应用。
2、根据权利要求1所述的通式I化合物用于治疗冲突相关性焦虑状态。
3、具有抗焦虑作用的药物，包括至少一种通式I的化合物或其可药用盐和，如果合适，赋形剂和/或辅料。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19721580A DE19721580A1 (de) | 1997-05-23 | 1997-05-23 | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
| DE19721580.7 | 1997-05-23 | ||
| US09/079,802 US5994347A (en) | 1997-05-23 | 1998-05-15 | For a process for treatment of anxiety and tension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1260717A true CN1260717A (zh) | 2000-07-19 |
| CN1150901C CN1150901C (zh) | 2004-05-26 |
Family
ID=26036759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988053748A Expired - Lifetime CN1150901C (zh) | 1997-05-23 | 1998-05-14 | 1-芳(烷)基咪唑啉-2-酮在治疗焦虑和紧张状态中的应用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5994347A (zh) |
| EP (1) | EP0979083B1 (zh) |
| JP (1) | JP4838403B2 (zh) |
| CN (1) | CN1150901C (zh) |
| AR (1) | AR012746A1 (zh) |
| AT (1) | ATE246926T1 (zh) |
| AU (1) | AU745536B2 (zh) |
| BG (1) | BG63378B1 (zh) |
| BR (1) | BR9809666A (zh) |
| CA (1) | CA2291075C (zh) |
| DE (2) | DE19721580A1 (zh) |
| DK (1) | DK0979083T3 (zh) |
| ES (1) | ES2205516T3 (zh) |
| HU (1) | HUP0003108A3 (zh) |
| IL (1) | IL132652A0 (zh) |
| NO (1) | NO325346B1 (zh) |
| NZ (1) | NZ500849A (zh) |
| PL (1) | PL193589B1 (zh) |
| PT (1) | PT979083E (zh) |
| RU (1) | RU2203055C2 (zh) |
| SK (1) | SK284258B6 (zh) |
| TR (1) | TR199902815T2 (zh) |
| TW (1) | TW579294B (zh) |
| WO (1) | WO1998052548A2 (zh) |
| ZA (1) | ZA984197B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
| US20050070537A1 (en) | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
| CA2531861A1 (en) * | 2003-07-11 | 2005-01-20 | Elbion Ag | Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| CA2576344C (en) | 2004-08-11 | 2010-10-05 | Cadbury Adams Usa Llc | Warming compositions and delivery systems therefor |
| US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044021A (en) * | 1971-10-21 | 1977-08-23 | American Cyanamid Company | Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism |
| DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
| US5869481A (en) * | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
-
1997
- 1997-05-23 DE DE19721580A patent/DE19721580A1/de not_active Withdrawn
-
1998
- 1998-05-14 NZ NZ500849A patent/NZ500849A/en unknown
- 1998-05-14 CA CA002291075A patent/CA2291075C/en not_active Expired - Lifetime
- 1998-05-14 DK DK98933532T patent/DK0979083T3/da active
- 1998-05-14 EP EP98933532A patent/EP0979083B1/de not_active Expired - Lifetime
- 1998-05-14 ES ES98933532T patent/ES2205516T3/es not_active Expired - Lifetime
- 1998-05-14 WO PCT/DE1998/001343 patent/WO1998052548A2/de active IP Right Grant
- 1998-05-14 HU HU0003108A patent/HUP0003108A3/hu unknown
- 1998-05-14 AT AT98933532T patent/ATE246926T1/de not_active IP Right Cessation
- 1998-05-14 AU AU83326/98A patent/AU745536B2/en not_active Expired
- 1998-05-14 CN CNB988053748A patent/CN1150901C/zh not_active Expired - Lifetime
- 1998-05-14 BR BR9809666-4A patent/BR9809666A/pt not_active Application Discontinuation
- 1998-05-14 IL IL13265298A patent/IL132652A0/xx not_active IP Right Cessation
- 1998-05-14 PT PT98933532T patent/PT979083E/pt unknown
- 1998-05-14 JP JP54979698A patent/JP4838403B2/ja not_active Expired - Lifetime
- 1998-05-14 RU RU99128109/14A patent/RU2203055C2/ru active
- 1998-05-14 TR TR1999/02815T patent/TR199902815T2/xx unknown
- 1998-05-14 DE DE59809285T patent/DE59809285D1/de not_active Expired - Lifetime
- 1998-05-14 SK SK1584-99A patent/SK284258B6/sk not_active IP Right Cessation
- 1998-05-14 PL PL98337090A patent/PL193589B1/pl not_active IP Right Cessation
- 1998-05-15 US US09/079,802 patent/US5994347A/en not_active Expired - Lifetime
- 1998-05-19 ZA ZA9804197A patent/ZA984197B/xx unknown
- 1998-05-20 TW TW087107848A patent/TW579294B/zh not_active IP Right Cessation
- 1998-05-22 AR ARP980102409A patent/AR012746A1/es not_active Application Discontinuation
-
1999
- 1999-10-29 NO NO19995300A patent/NO325346B1/no not_active IP Right Cessation
- 1999-11-04 BG BG103859A patent/BG63378B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Özalevli et al. | The effect of adding intrathecal magnesium sulphate to bupivacaine–fentanyl spinal anaesthesia | |
| Celerier et al. | Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process | |
| Borovikova et al. | Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation | |
| CHARLES J FISHER et al. | Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study | |
| KR100196674B1 (ko) | 디페닐부틸-피페라진카르복사미드를 이용한 물질 남용 장애의 치료방법 및 그를 함유하는 약제학적 조성물 | |
| EP0139535B1 (en) | Compositions for combatting toxaemia | |
| Doherty et al. | Local anesthetics as pain therapy in horses | |
| CN1150901C (zh) | 1-芳(烷)基咪唑啉-2-酮在治疗焦虑和紧张状态中的应用 | |
| Gajraj | Pregabalin for pain management | |
| Lin et al. | Attenuation of morphine tolerance by intrathecal gabapentin is associated with suppression of morphine-evoked excitatory amino acid release in the rat spinal cord | |
| Devoto et al. | Elevated dopamine in the medial prefrontal cortex suppresses cocaine seeking via D 1 receptor overstimulation | |
| CN111432882A (zh) | 对乙酰氨基酚-普瑞巴林组合和治疗疼痛的方法 | |
| AU664295B2 (en) | Use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension | |
| Heurich et al. | Influence of pain treatment by epidural fentanyl and bupivacaine on homing of opioid-containing leukocytes to surgical wounds | |
| Farr et al. | Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis | |
| Wang et al. | Evidence that spinal segmental nitric oxide mediates tachyphylaxis to peripheral local anesthetic nerve block | |
| KR100577626B1 (ko) | 1-아르(알크)일-이미다졸린-2-온을 포함하는, 불안 치료용 약제학적 조성물 | |
| Zabrodskii | The combined effect of anticholinesterase сompound DDVP and its antidote cholinesterase reactivator carboxim on implementation of cholinergic anti-inflammatory pathway | |
| Horrigan et al. | Replay: DYSTONIA AS A SIDE EFFECT OF NONNEUROLEPTICS | |
| Bates et al. | L-NAC and L-NAC methyl ester prevent and overcome physical dependence to fentanyl in male rats | |
| CN118001281A (zh) | 一种治疗或预防甲基苯丙胺成瘾的药物及应用 | |
| WO2023235500A1 (en) | Methods and pharmaceutical compositions for reducing the neuromodulatory effect of cocaine | |
| Mudge | Review of the analgesic, prokinetic, and anti-inflammatory uses of IV lidocaine. | |
| Anderson et al. | Comparative Anticonvulsant Activity of 1-Diethylacetyl-5, 5-Cyclopentamethylene Biuret, Sodium Diphenyl Hydantoinate and Sodium Pentobarbital in Mice. | |
| Kim et al. | A Comparison of Butorphanol and Fentanyl Administered in Conjunction with Ketorojac in Intravenous Patient Controlled Analgesia after Total Abdominal Hysterectomy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ELBION AG Free format text: FORMER OWNER: ARZNEIMITTELWERK DRESDEN GMBH Effective date: 20040401 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20040401 Address after: Ladd Boer, Germany Patentee after: Elbion AG Address before: Radebeul, Federal Republic of Germany Patentee before: Arzneimittelwerk Dresden GMBH |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: Radebeul, Germany Patentee after: ELBION GmbH Address before: Ladd Boer, Germany Patentee before: Elbion AG |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20081212 Address after: German Ingelheim Patentee after: Bo Ling G Engle Haim Witt Meidika LLC Address before: Radebeul, Germany Patentee before: ELBION GmbH |
|
| ASS | Succession or assignment of patent right |
Owner name: BURLINGAME ENGEL HEIM WITT MEDICS CO.,LTD. Free format text: FORMER OWNER: ELBIAN CO.,LTD. Effective date: 20081212 |
|
| C56 | Change in the name or address of the patentee |
Owner name: ELBIAN CO.,LTD. Free format text: FORMER NAME: ELBIAN STOCK CO., LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040526 |
|
| CX01 | Expiry of patent term |